Compounded semaglutide dosing errors: units, milligrams, and concentration checks

01

Why units, milliliters, and milligrams answer different questions

A medication order can contain several measurements that are related but not interchangeable. Milligrams state the amount of semaglutide. Milligrams per milliliter state concentration. Milliliters state the volume of liquid. The numbered “units” on a U-100 insulin syringe divide one milliliter into 100 volume markings; they do not state how many milligrams of semaglutide are present.

That distinction matters because compounded semaglutide is sold in multiple concentrations and containers. FDA says concentrations can differ among compounders and that one compounder may offer more than one concentration. Therefore, a direction learned for one labeled vial cannot safely be transferred to a refill, a different strength, a new pharmacy, or a different syringe.

Approved injectable semaglutide products use standardized, product-specific delivery systems and FDA-reviewed labeling. A compounded multidose vial is a different product pathway and has not undergone FDA premarket review for safety, effectiveness, or quality. A familiar ingredient name does not make the presentation, concentration, or instructions interchangeable.

02

What FDA's dosing-error reports show

FDA reported adverse events associated with overdoses from compounded injectable semaglutide. Some people sought medical attention or required hospitalization. Reported events included severe gastrointestinal symptoms, fainting, dehydration, pancreatitis, and gallstones, although an individual report does not by itself prove that semaglutide caused every event.

In many reports, patients unfamiliar with self-injection withdrew more than intended from a multidose vial. FDA described patients administering five to 20 times the intended amount. It also described clinicians miscalculating conversions from milligrams to units or milliliters, leading to five- or ten-fold errors.

These reports identify recurring system problems, not merely careless patients: variable concentration, unfamiliar packaging, instructions expressed in different measures, syringes much larger than the intended volume, and difficulty reaching a telehealth prescriber for clarification. A safe research checklist should examine the entire medication-use chain.

03

Reconcile four records before the first use and every refill

Ask the dispensing pharmacist to compare the prescriber's order, the pharmacy label, the written administration instructions, and the supplied device. The same product name across all four is not enough. The drug amount, concentration, intended volume, syringe scale, patient name, pharmacy identity, lot, and beyond-use date should agree.

Keep the original box, vial label, written directions, and pharmacy contact information together. When a refill looks different, do not assume a packaging refresh explains the change. Confirm whether concentration, total amount, vial size, directions, or syringe size changed and obtain corrected written instructions if necessary.

Do not ask a directory, search engine, social-media group, or dose calculator to resolve a patient-specific mismatch. Those sources cannot confirm what the prescriber intended or what the pharmacy actually compounded. The dispensing pharmacist is positioned to reconcile the preparation record and label; the prescriber is responsible for the clinical order.

• →Prescribed drug amount in milligrams
• →Labeled concentration in milligrams per milliliter
• →Written volume or syringe marking for that exact product
• →Syringe type and maximum volume
• →Pharmacy name, prescription number, lot, and beyond-use date
• →A reachable pharmacist and prescribing clinician

04

Warning signs that require clarification before use

Pause when instructions mention only “units” without a clear connection to the labeled concentration; when the vial concentration differs from the previous fill; when the syringe scale differs from the written directions; or when the telehealth portal, label, and prescription show different amounts. A handwritten sticker or online message should not silently replace the pharmacy's complete label and counseling.

Also investigate a missing pharmacy name, an address that does not match a board of pharmacy record, a label that names the telehealth brand as if it compounded the drug, or a product that arrived without patient-specific prescription information. These problems raise identity and sourcing questions separate from the mathematical conversion.

If too much may have been administered, contact the prescriber, pharmacist, Poison Control at 1-800-222-1222 in the United States, or emergency services as appropriate. Do not wait for a directory response. FDA encourages reporting medication errors and adverse events through MedWatch after urgent needs are addressed.

05

How provider researchers can compare dosing safeguards

Before enrollment, ask whether the program uses multidose vials or prefilled devices, which pharmacy dispenses, how concentration changes are communicated, who teaches device use, and whether a pharmacist is available after shipment. A promise of “easy dosing” is less useful than a documented process for reconciling every refill.

Look for a policy requiring instructions to identify both the drug amount and the corresponding volume for the exact concentration, without presenting a generic conversion chart as universal. Ask what happens when the pharmacy substitutes a concentration or syringe. The answer should include new patient-specific written directions and counseling, not an expectation that the patient will recalculate.

A provider's safeguards do not establish that compounded semaglutide is FDA-approved or appropriate for a particular person. They show whether the service acknowledges a known medication-error risk and has a credible way to prevent and correct discrepancies.

06

Limits of this guide

This article intentionally does not provide a conversion formula, syringe diagram, titration schedule, or recommended dose. Even mathematically correct arithmetic can be unsafe when the input concentration, prescription, device, or product identity is wrong. Individual treatment and overdose questions require licensed clinicians and pharmacists with the actual records.

FDA reports describe signals and cases, not the frequency of errors among all users or a comparison of every compounding pharmacy. The evidence supports specific precautions around variable presentations; it does not prove that every compounded product is mislabeled or that every reported symptom was caused by a dosing error.